Trikafta

ApprovedSmall molecule

UUniversity of British Columbia

Trikafta is one of 34 small molecule programs targeting Cystic Fibrosis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cystic FibrosisActive, not recruiting

Cystic FibrosisApproved

Active, not recruiting

Competition

Competitive Landscape

386 competitors in Cystic Fibrosis

#DrugCompanyPhaseTrials

Trikafta

UUniversity of British Columbia

Approved

4 2

Onglyza

AstraZeneca

Preclinical

2 3

Calciferol

Alnylam Pharmaceuticals

Preclinical

1 4

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

3 5

Actimmune

HHorizon Therapeutics Ireland DAC

Preclinical

2 6

Aztreonam Lysine

Gilead

Preclinical

5 7

Advil

KKenvue Brands

Preclinical

1 8

Capromorelin

UUniversity of Aarhus

Preclinical

1 9

Amitiza

SSucampo Pharma Americas, LLC

Preclinical

1 10

Serevent

GGlaxo Dba Glaxosmithkline

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Recruiting

Cystic Fibrosis

NCT05200429

Clinical

Trials by Indication[1]

Cystic Fibrosis4 trials

Trikafta for Patients With Non-cystic Fibrosis Bronchiectasis

Completed·EEmory University·Phase 4·NCT05743946·32 enrolled

Trikafta in Cystic Fibrosis Patients

Completed·EEmory University·Phase 2·NCT03506061·42 enrolled

Trikafta Exercise Study in Cystic Fibrosis

Recruiting·UUniversity of British Columbia··NCT05279040·20 enrolled

Show 1 more trial

Canadian Observational Study Evaluating the Long-term IMPACT of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators on People With CF

Recruiting·UUniversity of British Columbia··NCT05200429·500 enrolled

Tics1 trial

Impact of Rifabutin on the Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor

Completed·UUniversity of Southern California·Phase 4·NCT04840862·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Trikafta. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Trikafta compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Trikafta. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of British Columbia company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity of British Columbia

Trikafta

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Cystic Fibrosis4 trials

Tics1 trial

References

Drug Info

Quick Facts

Related News